Target Name: CCM2L
NCBI ID: G140706
Review Report on CCM2L Target / Biomarker Content of Review Report on CCM2L Target / Biomarker
CCM2L
Other Name(s): cerebral cavernous malformation 2-like | dJ310O13.5 | CCM2L variant 2 | CCM2 like scaffold protein | CCM2 like scaffolding protein | CCM2L_HUMAN | C20orf160 | Cerebral cavernous malformations 2 protein-like (isoform 2) | CCM2 like scaffold protein, transcript variant 2 | cerebral cavernous malformations 2 protein-like | Cerebral cavernous malformations 2 protein-like | CCM2-like

CCM2L: A Rare Brain Disorder with Unmet Treatment Options

CCM2L (Cerebral Cavernous Malformation 2-like) is a rare, progressive brain disorder that is characterized by the formation of abnormally shaped blood vessels (cavities) in the brain, which can lead to a range of serious cognitive and neurological symptoms. Despite its annoying symptoms, CCM2L is a potentially treatable condition that has captured the interest of researchers and pharmaceutical companies alike.

The exact cause of CCM2L is not known, but it is thought to involve a combination of genetic and environmental factors. Researchers have identified several genetic variations that are associated with an increased risk of developing CCM2L, but more research is needed to understand the full genetic spectrum of this condition.

In addition to its potential as a drug target, CCM2L has also been identified as a potential biomarker for the disease. This is because the formation of cavities in the brain is a hallmark of CCM2L, and can be detected using imaging techniques such as MRI or CT scans. By analyzing the size and shape of these cavities, researchers can get a sense of how much the disease has progressed and monitor the effectiveness of any treatments.

Another potential advantage of CCM2L as a drug target is its association with other neurological diseases. In addition to affecting cognition and behavior, CCM2L can also influence the immune system, making it a potential therapeutic target for neurodegenerative diseases.

Although there is currently no specific drug to cure CCM2L, research is ongoing to identify drugs that can improve disease progression and treatment efficacy. Phosphatidylserine, a phospholipid found in brain cells, has been shown to be a potential therapeutic target for CCM2L. Studies have shown that inhibiting phosphatidylserine levels can reduce the formation of cavities in CCM2L mice. Another potential target is the protein PDGF-BB, which has been shown to promote the formation of cavities in CCM2L mice.

In conclusion, CCM2L is a rare and progressive brain disorder that is characterized by the formation of abnormal blood vessels in the brain. While there is currently no specific drug to cure CCM2L, research is ongoing to discover drugs that can improve disease progression and treatment effectiveness. drug. Phosphatidylserine and PDGF-BB are potential targets for the treatment of CCM2L. Further research is needed to understand the full potential of these targets and to develop effective therapies for this progressive and debilitating condition.

Protein Name: CCM2 Like Scaffold Protein

The "CCM2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCM2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200